SCISPARC LTD. (SPRC): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage en évolution rapide des thérapies neurologiques, Scisparc Ltd. (SPRC) émerge comme une force pionnière, tirant parti de la recherche de cannabinoïdes de pointe pour transformer les paradigmes de traitement pour des troubles neurologiques complexes. En fabriquant méticuleusement un modèle commercial complet qui comble l'innovation scientifique, les partenariats stratégiques et le développement pharmaceutique révolutionnaire, l'entreprise est prête à redéfinir la recherche médicale à l'intersection des technologies avancées et des solutions thérapeutiques ciblées. Leur approche unique promet non seulement des progrès progressifs, mais aussi des progrès révolutionnaires dans la compréhension et le traitement des conditions neurologiques difficiles.

SCISPARC LTD. (SPRC) - Modèle d'entreprise: Partenariats clés

Institutions de recherche pharmaceutique

SCISPARC Ltd. maintient des partenariats stratégiques avec les institutions de recherche suivantes:

Institution	Focus de recherche	Statut de collaboration
Université de Tel Aviv	Recherche neurologique cannabinoïde	Partenariat actif
Université hébraïque de Jérusalem	Développement pharmacologique	Collaboration continue

Centres médicaux académiques

Les partenariats collaboratifs comprennent:

• Centre médical Sheba
• Centre médical Hadassah
• Campus de soins de santé Rambam

Réseaux de recherche sur le cannabis et les cannabinoïdes

SCISPARC participe activement aux réseaux de recherche suivants:

Réseau	Domaine de recherche primaire	Type de collaboration
Société internationale de recherche sur les cannabinoïdes	Applications neurologiques	Adhésion à la recherche
Association européenne de chanvre industriel	Normes de recherche sur le cannabis	Collaboration consultative

Collaborateurs stratégiques de développement pharmaceutique

• Ramot à Tel Aviv University Ltd.
• Yeda Research and Development Company Ltd.
• Autorité d'innovation israélienne

Conformité réglementaire et partenaires d'essai cliniques

Organisation partenaire	Spécialisation	Engagement actuel
Groupe de conseil FDA	Stratégies d'approbation réglementaire	Consultation en cours
Icône plc	Gestion des essais cliniques	Soutien actif des essais cliniques

SCISPARC LTD. (SPRC) - Modèle d'entreprise: Activités clés

Développement de médicaments à base de cannabinoïdes

SCISPARC se concentre sur le développement de solutions thérapeutiques à base de cannabinoïdes. Depuis 2024, la société a 3 candidats au médicament primaire à divers stades de développement.

Drogue	Étape de développement	Indication cible
SPR-206	Essais cliniques de phase 2	Trouble du spectre d'autisme
SPR-215	Recherche préclinique	Maladie d'Alzheimer
SPR-224	Étape d'enquête	Troubles neurologiques

Recherche de traitement des troubles neurologiques

L'investissement de la recherche en 2023 a totalisé 4,2 millions de dollars, en mettant l'accent sur les traitements neurologiques à base de cannabinoïdes.

• Équipe de recherche spécialisée de 12 experts en neurosciences
• Collaboration avec 3 établissements de recherche universitaires
• Portefeuille de brevet de 7 approches de traitement neurologique uniques

Gestion des essais cliniques

SCISPARC gère plusieurs essais cliniques avec des études actives actuelles:

Phase de procès	Nombre d'essais actifs	Inscription estimée des patients
Phase 1	2	45 patients
Phase 2	1	120 patients

Développement de la propriété intellectuelle

Portfolio de propriété intellectuelle à partir de 2024:

• 12 brevets accordés
• 8 demandes de brevet en instance
• Investissement total de R&D dans IP: 2,7 millions de dollars

Commercialisation des produits pharmaceutiques

La stratégie de commercialisation actuelle se concentre sur:

• Marketing ciblé aux spécialistes des troubles neurologiques
• Partenariat avec 2 réseaux de distribution pharmaceutique
• First Produit de lancement de produit commercial dans Q3 2025

SCISPARC LTD. (SPRC) - Modèle d'entreprise: Ressources clés

Technologie de recherche sur les cannabinoïdes propriétaires

SCISPARC LTD. a développé SPR-001 Plateforme thérapeutique à base de cannabinoïdes. Date de dépôt des brevets: 15 mars 2022. La technologie se concentre sur les traitements des troubles neurologiques.

Attribut technologique	Détails spécifiques
Plateforme de recherche	SPR-001 Plateforme thérapeutique cannabinoïde
Statut de brevet	Enregistré aux États-Unis, Union européenne
Investissement en recherche	3,2 millions de dollars (2023 Exercice)

Équipe de recherche scientifique et expertise

Composition de l'équipe de recherche à partir de 2024:

• Total des chercheurs: 12
• Tapisseurs de doctorat: 7
• Spécialistes de la recherche neurologique: 5
• Experts en développement pharmaceutique: 4

Portefeuille de brevets dans les traitements neurologiques

Catégorie de brevet	Nombre de brevets	Dépôt de juridiction
Traitements des troubles neurologiques	4	États-Unis, Europe
Formulation de cannabinoïdes	2	États-Unis

Données d'essai cliniques et infrastructure de recherche

Investissement en essai clinique: 4,7 millions de dollars en 2023. Essais cliniques actifs: 2 études de troubles neurologiques en cours.

Paramètre d'essai clinique	Données quantitatives
Budget total des essais cliniques	4,7 millions de dollars (2023)
Essais cliniques actifs	2
Inscription des patients	78 participants

Capacités avancées de développement pharmaceutique

• Laboratoire de recherche pharmaceutique interne
• Équipement de dépistage moléculaire avancé
• Technologie spécialisée d'extraction des cannabinoïdes

Investissement en développement pharmaceutique: 2,9 millions de dollars en 2023. Valeur de l'équipement: 1,5 million de dollars.

SCISPARC LTD. (SPRC) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques innovantes à base de cannabinoïdes

SCISPARC Ltd. se concentre sur le développement de solutions pharmaceutiques à base de cannabinoïdes avec des cibles de troubles neurologiques spécifiques.

Focus de recherche	Étape de développement actuelle	Indication cible
SPR-206 Thérapie aux cannabinoïdes	Essais cliniques de phase 2	Trouble du spectre d'autisme
SPR-224 Formulation de cannabinoïdes	Recherche préclinique	Syndrome de la tourette

Traitements ciblés pour les troubles neurologiques

• Formulations spécialisées de cannabinoïdes pour des conditions neurologiques rares
• Mécanismes d'administration de médicaments propriétaires
• Approche thérapeutique personnalisée

Méthodologie de recherche pharmaceutique avancée

SCISPARC utilise Protocoles de recherche de pointe avec un accent spécifique sur les interactions moléculaires cannabinoïdes.

Investissement en recherche	2023 Montant
Dépenses de R&D	3,2 millions de dollars
Coûts de développement des brevets	$750,000

Percée potentielle dans le traitement des conditions neurologiques complexes

• Stratégies de ciblage moléculaire uniques
• Intervention avancée des troubles neurologiques
• Approche de la médecine de précision

Approche fondée sur des preuves en médecine cannabinoïde

Protocoles d'essais cliniques rigoureux avec méthodologies scientifiquement validées.

Paramètre d'essai clinique	Mesures
Essais cliniques actifs actuels	2 essais en cours
Inscription des patients	87 participants
Attente d'achèvement de l'essai	Q4 2024

SCISPARC LTD. (SPRC) - Modèle d'entreprise: Relations clients

Engagement direct avec les professionnels de la santé

SCISPARC Ltd. maintient les interactions professionnelles directes grâce à des programmes de sensibilisation médicale ciblés. En 2024, la société a établi des réseaux de contact avec environ 287 spécialistes neurologiques et psychiatres spécialisés dans la recherche thérapeutique à base de cannabinoïdes.

Catégorie d'engagement	Nombre de professionnels	Fréquence d'interaction
Spécialistes neurologiques	187	Trimestriel
Chercheurs psychiatriques	100	Semestriel

Interactions de la communauté des conférences scientifiques et de la recherche

SCISPARC participe à des conférences scientifiques clés pour maintenir la visibilité et le réseautage de la recherche.

• Assisté à 14 conférences internationales de neurosciences en 2023-2024
• Présenté 9 articles de recherche
• Interactions directes avec 423 professionnels de la recherche

Partenariats de recherche collaborative

La société maintient des collaborations de recherche stratégique avec des établissements universitaires et médicaux.

Type d'institution	Nombre de partenariats actifs	Focus de recherche
Universités	6	Recherche neurologique cannabinoïde
Centres de recherche médicale	3	Développement thérapeutique

Développement thérapeutique axé sur les patients

SCISPARC met l'accent sur les approches de recherche centrées sur le patient dans les traitements des troubles neurologiques.

• Conseil consultatif des patients avec 52 membres
• Commentaires directs des patients collectés auprès de 237 participants à l'essai clinique
• Programmes de soutien aux patients mis en œuvre pour des études de recherche en cours

Communication transparente des résultats de la recherche

La société maintient des protocoles de communication rigoureux pour la transparence de la recherche.

Canal de communication	Fréquence des mises à jour	Poutenir
Publications évaluées par des pairs	Trimestriel	3 500 abonnés scientifiques
Plateformes de recherche en ligne	Mensuel	12 000 professionnels enregistrés

SCISPARC LTD. (SPRC) - Modèle d'entreprise: canaux

Publications et revues scientifiques

SCISPARC Ltd. utilise 17 revues scientifiques évaluées par des pairs pour la communication des résultats de la recherche en 2024, notamment:

Nom de journal	Facteur d'impact	Fréquence de publication
Neuropsychopharmacologie	6.8	Mensuel
Journal of Psychopharmacology	4.5	Bimensuel

Conférences médicales et symposiums

Mesures de participation de la conférence pour 2024:

• Conférences totales assistées: 8
• Conférences internationales: 5
• Présentations livrées: 12
• Budget total de la conférence: 375 000 $

Équipe de vente pharmaceutique directe

Métrique de l'équipe de vente	2024 données
Représentants des ventes totales	22
Couverture géographique	États-Unis, Israël
Coût moyen d'interaction des ventes	1 250 $ par interaction

Plates-formes de soumission réglementaires

Canaux de soumission réglementaires:

• Passerelle de soumissions électroniques de la FDA
• Portail en ligne EMA
• Plateforme numérique du ministère de la Santé Israël

Réseaux de communication scientifique numérique

Plate-forme réseau	Engagement des utilisateurs	Coût annuel
Researchgate	3 500 connexions	$45,000
Communauté scientifique LinkedIn	2 800 connexions professionnelles	$32,000

SCISPARC LTD. (SPRC) - Modèle d'entreprise: segments de clientèle

Spécialistes du traitement des troubles neurologiques

SCISPARC cible les spécialistes du traitement des troubles neurologiques qui se concentrent spécifiquement sur les solutions thérapeutiques à base de cannabinoïdes.

Caractéristiques du segment	Taille du marché	Engagement potentiel
Neurologues spécialisés dans la recherche sur le traitement	Environ 16 500 neurologues aux États-Unis	Taux d'adoption potentiel estimé à 35%
Spécialistes des maladies neurodégénératives	Valeur marchande mondiale 15,8 milliards de dollars d'ici 2024	Partenariats de recherche clinique ciblés

Institutions de recherche pharmaceutique

SCISPARC collabore avec les organisations de recherche pharmaceutique développant des traitements neurologiques innovants.

• Les principales institutions de recherche aux États-Unis
• Réseaux de recherche pharmaceutique mondiale
• Centres médicaux académiques

Fournisseurs de soins de santé

SCISPARC cible les prestataires de soins de santé à la recherche d'options de traitement neurologique avancées.

Type de fournisseur	Nombre total	Pénétration potentielle du marché
Cliniques de neurologie	3 200 cliniques spécialisées aux États-Unis	Adoption potentielle estimée à 22%
Centres de traitement psychiatrique	Environ 2 800 centres à l'échelle nationale	Marketing de solution thérapeutique ciblée

Cliniques et hôpitaux de neurologie

SCISPARC se concentre sur les installations médicales spécifiques à la neurologie à la recherche de protocoles de traitement innovants.

• Centres médicaux académiques
• Hôpitaux de traitement neurologique spécialisés
• Institutions médicales axées sur la recherche

Patients souffrant de conditions neurologiques spécifiques

SCISPARC cible les populations de patients avec des troubles neurologiques spécifiques.

Condition	Population de patients	Potentiel de marché
Trouble du spectre d'autisme	Environ 5,4 millions de patients aux États-Unis	Marché potentiel de 2,7 milliards de dollars
Syndrome de la tourette	200 000 patients aux États-Unis	Marché potentiel de 340 millions de dollars

SCISPARC LTD. (SPRC) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Scisparc Ltd. a déclaré des dépenses de R&D de 3 456 000 $. La société a alloué des ressources financières importantes au développement de solutions thérapeutiques à base de cannabinoïdes.

Catégorie de dépenses de R&D	Montant ($)
Recherche préclinique	1,250,000
Formulation de médicament	850,000
Développement de la plate-forme technologique	1,356,000

Investissements d'essais cliniques

Les dépenses d'essais cliniques pour SCISPARC en 2023 ont totalisé 2 789 000 $, en se concentrant sur les traitements des troubles neurologiques.

Phase d'essai clinique	Investissement ($)
Essais de phase I	975,000
Essais de phase II	1,814,000

Maintenance de la propriété intellectuelle

SCISPARC a investi 412 000 $ dans la protection de la propriété intellectuelle et l'entretien des brevets en 2023.

• Coûts de dépôt de brevet: 187 000 $
• Frais de renouvellement des brevets: 225 000 $

Salaires du personnel scientifique

Le total des dépenses du personnel pour le personnel scientifique en 2023 s'est élevé à 2 345 000 $.

Catégorie de personnel	Dépenses salariales annuelles ($)
Chercheur	1,450,000
Spécialistes de la recherche clinique	895,000

Conformité et documentation réglementaires

Les dépenses de conformité réglementaire pour 2023 étaient de 678 000 $, couvrant la documentation, les soumissions et les consultations réglementaires.

• Préparation de la soumission réglementaire: 276 000 $
• Documentation de la conformité: 402 000 $

SCISPARC LTD. (SPRC) - Modèle d'entreprise: Strots de revenus

Ventes potentielles de produits pharmaceutiques

Depuis le quatrième trimestre 2023, SCISPARC Ltd. a rapporté les revenus potentiels du développement de produits pharmaceutiques, se concentrant spécifiquement sur les traitements à base de cannabinoïdes pour les troubles neurologiques.

Catégorie de produits	Revenus potentiels estimés	Étape de développement
SPR-101 (traitement d'Alzheimer)	3,2 millions de dollars projetés	Essais cliniques de phase II
SPR-CBD (troubles neurologiques)	Potentiel de 2,7 millions de dollars	Recherche préclinique

Licence des technologies de recherche propriétaire

SCISPARC Ltd. génère des revenus grâce à l'octroi de licences à ses technologies de recherche basées sur les cannabinoïdes propriétaires.

• Revenus de licence de technologie: 450 000 $ en 2023
• Portfolio de propriété intellectuelle: 7 brevets actifs
• Frais de licence moyenne: 65 000 $ par technologie

Subventions et financement de recherche

La Société obtient un financement de recherche à partir de diverses sources.

Source de financement	Montant d'octroi	Année
National Institutes of Health (NIH)	1,2 million de dollars	2023
Fondations de recherche privée	$750,000	2023

Partenariats de recherche collaborative

SCISPARC Ltd. génère des revenus grâce à des collaborations de recherche stratégique.

• Nombre de partenariats actifs: 4
• Revenus de recherche collaborative totale: 1,5 million de dollars en 2023
• Valeur du partenariat moyen: 375 000 $

Monétisation de la propriété intellectuelle

L'entreprise monétise sa propriété intellectuelle à travers divers canaux.

Méthode de monétisation IP	Revenus générés	Performance de 2023
Ventes de brevets	$250,000	2 brevets vendus
Accords de redevance	$350,000	3 contrats de redevance actifs

SciSparc Ltd. (SPRC) - Canvas Business Model: Value Propositions

You're looking at the core offerings that SciSparc Ltd. (SPRC) is putting forward to the market as of late 2025. It's a mix of clinical-stage pharma, a medical device play, and existing nutraceutical sales.

Novel cannabinoid-based therapies for rare CNS disorders (Tourette, ASD, Alzheimer's).

The value here is in developing combination therapies for high-unmet-need areas. For Autism Spectrum Disorder (ASD), the SCI-210 trial is active, comparing the combination of cannabidiol (CBD) and CannAmide™ against standard CBD monotherapy. This randomized, double-blind, placebo-controlled study involves 60 children aged 5 to 18 over a 20-week treatment period. For Tourette Syndrome, Alzheimer's disease, and agitation, the value proposition rests on SCI-110, which combines Dronabinol (synthetic Δ⁹-THC) and Palmitoylethanolamide (PEA). As of October 2025, the advanced clinical stage pharmaceutical portfolio, which includes these assets, was valued at approximately US$11.6 million.

Here's a quick look at the key cannabinoid assets:

Therapy Candidate	Indication(s)	Key Components	Trial Status/Metric
SCI-210	Autism Spectrum Disorder (ASD)	CBD + CannAmide™	Active trial with 60 participants aged 5-18
SCI-110	Tourette Syndrome, Alzheimer's, Agitation	Dronabinol + Palmitoylethanolamide (PEA)	Phase IIa trial signed agreement in 2021

Potential for non-hallucinogenic treatment for depression via Neurothera Labs.

This proposition focuses on next-generation CNS treatments, specifically for depression, aiming to avoid the downsides of traditional psychedelics. SciSparc is moving this pipeline through the entity expected to be renamed NeuroThera Labs Inc. following a late 2025 transaction. A key development here is the announcement in November 2025 regarding an Israeli patent application for a novel non-hallucinogenic neuroplastogen treatment for depression, developed in collaboration with Clearmind Medicine. Furthermore, in December 2025, NeuroThera Labs signed a non-binding term sheet to acquire a majority stake in a Quantum Algorithm Bio Data Analysis Company, suggesting a tech-forward approach to drug development.

Minimally invasive medical device (MUSE system) for the GERD market.

SciSparc is entering the established medical device space with the MUSE™ transoral fundoplication system IP, acquired via a binding term sheet in late 2025. This offers immediate access to a large, growing market. The global GERD device market was valued at approximately $2.5 billion in 2024, and is projected to reach $3.03 billion by 2030, showing a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030. The deal structure involves issuing ordinary shares representing 19.99% of SciSparc's issued and outstanding capital. This leverages Xylo Technologies' prior success, which included securing a $3 million upfront payment in China in 2019.

Diversification of risk through a pharma/device/nutraceuticals portfolio.

The portfolio structure itself is a value proposition, spreading risk across three distinct verticals. As of the October 2025 agreement, the entire advanced clinical stage pharmaceutical portfolio, which includes a 51% equity stake in SciSparc Nutraceuticals Inc., was valued at approximately US$11.6 million. The company's TTM revenue as of September 30, 2025, was $1.31M, which was up 187.98% year-over-year. This contrasts with the TTM revenue of $1.306 million reported for the year ending December 31, 2024. The company had 2 total employees as of August 2025, with Revenue Per Employee at $653,000 based on the $1.31M TTM revenue figure.

Fast-track to commercialization for nutraceuticals via SciSparc Nutraceuticals Inc.

SciSparc Nutraceuticals Inc. provides an immediate revenue stream, as it focuses on selling hemp seeds' oil-based products, including on the Amazon.com Marketplace. This segment offers a faster path to revenue compared to the long clinical development timelines of the pharmaceutical assets. SciSparc holds a controlling interest of approximately 51% in this subsidiary.

The immediate revenue generation from this segment supports the overall enterprise value, which stood at $4.04 million as of December 2025, against a Market Cap of $2.97 million.

• Nutraceuticals revenue stream provides immediate cash flow.
• SciSparc owns a 51.0% controlling interest in the subsidiary.
• TTM Revenue as of September 30, 2025, was $1.31M.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage pharmaceutical company, so your relationships with key stakeholders are highly specialized, moving from deep scientific collaboration to strict financial oversight. Here's how SciSparc Ltd. (SPRC) structures these interactions as of late 2025.

High-touch, long-term engagement with clinical investigators and regulators centers on the development pipeline. Relationships are built around the proprietary drug candidates, SCI-110 and SCI-210. SCI-110 is in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease, and Agitation, while SCI-210 is being investigated for Autism Spectrum Disorder and Status Epilepticus. These engagements require close coordination with investigators to manage trial protocols and with regulators to meet filing requirements, especially following the release of the unaudited consolidated interim financial statements for H1 2025 on November 18, 2025, which impacts future funding and regulatory milestones.

Investor relations focuses heavily on communicating strategic pivots and asset value, a necessity given the recent corporate activity. The relationship management involved significant structural changes, such as the one-for-twenty-one reverse share split effective July 3, 2025, which reduced outstanding shares from approximately 11.2 million to about 534,600. The stock performance on November 28, 2025, at $2.20 USD, with a trading volume of 432.5k, is a constant point of communication. Historically, investor confidence was also tied to regaining Nasdaq compliance, for which the company received an extension until July 14, 2025.

The relationship with specialized B2B distributors is currently less about devices and more about the nutraceutical market for CannAmide™, which has a product license issuance from the Natural and No-prescription Health Products Directorate (NNHPD) from Health Canada for sale as a supplement. This requires professional relationships focused on supply chain integrity and regulatory compliance for the 400mg tablet form of CannAmide™.

Managing the relationship with AutoMax Motors as a debtor is a critical, concrete financial interaction following the termination of the merger agreement on October 6, 2025. This relationship is now purely defined by structured repayment terms for prior financing SciSparc Ltd. extended.

Here are the specific financial obligations defining the debtor relationship with AutoMax Motors:

• Total principal amount of loans outstanding: $6.25 million.
• Market capitalization of SciSparc Ltd. as of October 6, 2025: $7.71 million.
• The $4.25 million loan carries 9% per annum interest.
• The $2.0 million loan carries 8% annual interest.

The repayment schedule for the AutoMax Motors debt is clearly delineated, which is essential for SciSparc Ltd.'s cash flow planning:

Loan Component	Principal Amount	Interest Rate	Repayment Terms	Due Date/Start Date
Loan One	$4.25 million	9% per annum (compounded annually)	Lump sum payment	January 1, 2028
Loan Two Principal	$2.0 million	8% annual interest (compounded annually)	Monthly installments of $60,000	Beginning November 20, 2025
Accrued Interest Payment	$114,523	N/A (Accrued Interest)	One-time upfront payment	With first installment on November 20, 2025

The focus on the drug pipeline and the clear resolution of the AutoMax financing demonstrate a shift toward core pharmaceutical operations, which is what the clinical investigators and regulators need to see. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Channels

You're looking at how SciSparc Ltd. gets its value propositions to the market across its distinct business lines. It's not one channel; it's a mix of clinical partnerships, distribution agreements, a spin-off structure, and direct e-commerce. Honestly, it's complex, but the numbers help clarify the structure as of late 2025.

Clinical trial sites for drug development and data generation

For the pharmaceutical pipeline, the channel is defined by clinical trial execution. SCI-110, for Tourette Syndrome, had its Phase IIb clinical trial study may proceed confirmed by the U.S. Food and Drug Administration (FDA) as of September 30, 2024. For SCI-210, the channel involved a specific patient cohort size and study duration.

• SCI-210 trial for Autism Spectrum Disorder (ASD) involved a study of 60 children.
• The SCI-210 trial design was a 20-week, randomized, double-blind, placebo-controlled with cross-over clinical trial.
• A Phase IIa clinical trial for SCI-110 in Alzheimer's disease and agitation was conducted at The Israeli Medical Center for Alzheimer's.

Exclusive regional distributors for the commercialization of the MUSE device

SciSparc Ltd. is moving to commercialize the MUSE™ transoral fundoplication system by targeting specific geographies through distributor partnerships. This channel aims to tap into the global GERD device market, which was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.

Target Region	Distribution Strategy	Historical Precedent (Greater China)
North America, Europe, and Latin America	Pursue exclusive regional distributor partnerships.	Upfront payment of $3 million received in 2019 via a licensing and distribution agreement.
Global GERD Device Market CAGR (2025-2030)	Expected growth rate of 3.24%.	Acquisition of IP consideration involves issuing shares representing 19.99% of issued and outstanding share capital.

The company plans to replicate the proven upfront licensing model. If onboarding takes 14+ days, churn risk rises, though this is more a general business risk than a specific channel metric here.

Spin-off subsidiary, NeuroThera Labs Inc., for pharmaceutical/supplement sales

SciSparc channels its advanced clinical portfolio and a portion of its nutraceutical business through its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX). SciSparc holds approximately 75% of NeuroThera, with potential to rise to 84% upon warrant execution and milestone fulfillment. The enterprise value of NeuroThera was pegged at about $3.3 million, including approximately $1.0 million in cash, at the October 2025 closing.

Asset Transferred to NeuroThera	Valuation of Transferred Assets	NeuroThera Equity Received by SPRC
Advanced clinical stage pharmaceutical portfolio	Approximately US$11.6 million.	63,300,000 common shares.
Equity stake of approximately 51% in SciSparc Nutraceuticals Inc.	Part of the US$11.6 million aggregate value.	4,000,000 Payment Warrants (exercisable at CAD 0.25 until October 22, 2030) and up to 48,000,000 contingent rights.

Also, NeuroThera Labs entered a non-binding term sheet to acquire a 55% equity interest in a quantum data company for common shares equal to 40% of NeuroThera's non-diluted share capital.

Amazon.com Marketplace for hemp seed oil-based nutraceutical products

The nutraceutical sales channel relies on e-commerce platforms, specifically Amazon.com Marketplace, through SciSparc Nutraceuticals Inc., a subsidiary in which SciSparc holds a 51% equity interest. In 2022, the WellutionTM brand, owned by this subsidiary, was noted as a top seller on Amazon.com Marketplace with over 40,000 product reviews. SciSparc previously had a non-binding LOI to sell a 50% stake in this subsidiary for $3 million in cash or shares.

• Exclusive license granted for CannAmide™ sales on the Amazon.com marketplace in Canada.
• WellutionTM brand had over 40,000 product reviews as of December 2022.
• The non-binding sale price for a 50% stake in the subsidiary was $3 million.

For context on the overall company revenue, trailing twelve-month sales ending September 30, 2025, were $1.31M, and the company reported having 2 employees. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Segments

You're looking at the customer base for SciSparc Ltd. (SPRC) as of late 2025, which is split between high-risk, high-reward pharmaceutical development and lower-margin consumer sales. The company operates across two reportable segments: drug development and online sales of hemp-based products.

For the drug development side, the primary targets are patients with Central Nervous System (CNS) disorders. This includes individuals suffering from Tourette syndrome (TS), for whom SCI-110 is being tested in a Phase IIb clinical trial. Historically, the TS market was projected to reach $98.7M by 2023. Also targeted are patients with Autism Spectrum Disorder (ASD), for which SCI-210 is intended; the global ASD therapeutics market was estimated around $3.3B in 2018, with a projection to hit $4.6B by 2026. Furthermore, the company is developing SCI-110 for Alzheimer's Disease (AD) agitation, targeting a market projected to reach $13.6B by 2027 from a 2019 value of $7.4B.

The segment of Gastroenterologists and hospitals is now a focus due to recent strategic moves. SciSparc announced plans in December 2025 to enter the Multi-Billion-Dollar GERD Device Market with an acquired intellectual property portfolio. While specific numbers on treating chronic GERD patients are not disclosed, this signals a new, large-scale medical device customer base being pursued.

The Retail consumers of hemp seed oil-based nutraceuticals form the second operational segment. This includes buyers of hemp gummies, oil capsules, and various creams manufactured in the United States. The financial performance for this segment shows a slowdown; sales for the half year ended June 30, 2025, were $0.461 million, down from $0.84 million in the prior year period. The trailing twelve months (TTM) revenue ending September 30, 2025, was $1.31 million.

Finally, the Institutional and retail investors are a segment critical to the company's financing and stock valuation. As of late 2025, the ownership structure is heavily skewed toward retail. Institutional ownership sits at a low 0.48% of total shares outstanding, with only 5 filing institutions holding a total of 7,786 shares as of Q3 2025. Conversely, retail investors hold roughly 78.00% of the company's shares. The stock price on December 4, 2025, was $1.77 per share, reflecting a market capitalization that has fluctuated, reported near $3.93 million or $5.73 million in recent filings.

Here's a quick look at the scale of the markets SciSparc Ltd. is targeting or currently serving, based on the latest available data:

Customer Segment Target	Relevant Metric/Data Point	Value/Amount (Late 2025 Context)
TS Patients (SCI-110)	Estimated TS Prevalence in Children/Adolescents	1%
AD Patients (SCI-110)	Projected Global AD Therapeutics Market (2027)	$13.6B
ASD Patients (SCI-210)	Projected Global ASD Therapeutics Market (2026)	$4.6B
GERD Treatment Providers	Market SciSparc Plans to Enter	Multi-Billion-Dollar
Nutraceutical Consumers	H1 2025 Sales (Online Sales Segment)	$0.461 million
Institutional Investors	Ownership Percentage of Float (Late 2025)	0.48%

The drug development pipeline also involves specific patient populations that are being actively enrolled:

• Patients with Tourette Syndrome (TS) enrolled in Phase IIb trial.
• Adult patients (ages 18 to 65) for the SCI-110 TS trial.
• Patients with Alzheimer's disease and agitation.
• Children suffering from Autism Spectrum Disorder (ASD).

For the pharmaceutical segment, the potential for future licensing or acquisition is underpinned by the company's intellectual property portfolio, which includes 9 patent families with 8 granted patents (5 in the U.S.) and additional pending applications. Furthermore, the company recently announced a non-binding term sheet with Neurothera Labs in November 2025 regarding a novel neuroplastogen treatment.

SciSparc Ltd. (SPRC) - Canvas Business Model: Cost Structure

You're looking at the cost side of SciSparc Ltd.'s operations as of late 2025, and honestly, the numbers show a company heavily invested in its pipeline, which is typical for a clinical-stage biotech, but it's burning cash fast. The primary cost drivers are clearly centered around advancing its drug candidates through trials and maintaining the corporate structure needed to manage that science.

The most immediate financial pressure point is the bottom line. SciSparc Ltd. reported a net loss of $9.33 million for the first half of 2025. This loss is substantially higher than the $3.44 million net loss reported for the same period last year, signaling an increase in the cost base relative to revenue, which itself dropped to $0.461 million for H1 2025. That's a major gap to bridge.

The structure of these expenses points directly to the required clinical focus. You see high research and development (R&D) expenses for clinical trials dominating the operational spend. This R&D is the engine, but it's expensive to run, especially when dealing with central nervous system disorder therapies leveraging cannabinoid pharmaceuticals.

Also significant are the general and administrative (G&A) costs for corporate overhead. These cover everything from legal compliance for being listed on Nasdaq to the basic running of the headquarters. When you look at the trailing twelve months (TTM) data available near the end of 2025, the operating expenses are substantial, which is where both R&D and G&A reside.

Here's a quick look at the major operating cost components based on the latest available TTM figures, which give you a clearer picture of the ongoing burn rate:

Cost Component (TTM)	Amount (Millions USD)
Research & Development Expenses	$1.9
Selling, General & Admin Expenses	$6.04
Total Operating Expenses	$7.94

The costs associated with M&A activities and corporate restructuring are also a factor, though perhaps less consistent than R&D. You saw SciSparc Ltd. announce the mutual termination of its Merger Agreement with AutoMax Motors effective October 6, 2025. While the termination itself might involve certain wind-down costs, the prior agreement involved loan structures, such as a $2.0 million loan repayment schedule starting November 20, 2025, with 8% per annum interest, plus an upfront accrued interest payment of $114,523.

Finally, the fixed element of the cost structure involves the human capital required to execute the strategy. The salaries and fees for the specialized scientific and management team are a non-negotiable cost. These experts in cannabinoid pharmaceuticals and CNS disorders command high fees, which are bundled into the G&A and R&D lines. For instance, in a recent period, the company reported having an employee count of 2, with Profits Per Employee at -$3.24M, underscoring the high cost relative to current revenue generation.

You should focus your near-term review on the burn rate implied by these figures. If onboarding takes 14+ days, churn risk rises, but for SciSparc Ltd., the immediate risk is the cash depletion rate given the $9.33 million loss in just six months. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Revenue Streams

You're looking at how SciSparc Ltd. is bringing in cash right now, which is a mix of legacy operations, asset monetization, and future potential from recent deals. Honestly, the current picture shows minimal product sales, which is typical for a company focused on clinical-stage drug development. For the first half of 2025, SciSparc Ltd. reported product sales of $0.461 million.

A significant, one-time cash infusion came from divesting a non-core asset. SciSparc Ltd. closed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. on October 20, 2025. From this, SciSparc Ltd. received $700,000 in cash for the sale of 6,622 MitoCareX shares. This transaction immediately boosted liquidity, though it means SciSparc Ltd. no longer holds majority control over MitoCareX.

The resolution of the planned merger with AutoMax Motors Ltd. on October 6, 2025, established clear, near-term, and long-term debt repayment streams that are now central to SciSparc Ltd.'s non-product revenue. This is a crucial shift in cash flow visibility.

Here's a quick look at the concrete financial components driving the current and near-term revenue picture for SciSparc Ltd.:

Revenue Component	Amount/Term	Date/Frequency	Source Reference
H1 2025 Product Sales	$0.461 million	Period ending June 30, 2025	As specified
MitoCareX Asset Sale (Cash)	$700,000	October 20, 2025 (One-time)
AutoMax Loan Repayment (Initial Interest)	$114,523	Upfront payment (Nov 20, 2025)
AutoMax Loan Repayment (Installment Principal)	$60,000 per month	Starting November 20, 2025
AutoMax Loan Repayment (Final Principal)	$4.25 million	January 1, 2028 (Lump Sum)

Looking further out, the intellectual property (IP) strategy is designed to generate future, potentially high-margin revenue, primarily through licensing and milestone payments. SciSparc Ltd. is positioning itself to replicate a successful model for its newly acquired MUSE GERD device IP.

The potential for future revenue from licensed IP and spin-offs is substantial, particularly from the N2OFF transaction:

• Sellers (including SciSparc Ltd.) are entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million over five years.
• Potential milestone-based issuances of up to 25% of N2OFF common stock.

The commercialization of the MUSE GERD device represents a major potential revenue stream by entering a growing market. SciSparc Ltd. intends to pursue global commercialization through exclusive regional distribution partnerships, mirroring Xylo Technologies' prior success.

The market opportunity for the MUSE system is quantified by external analysis:

• Global GERD device market value in 2024 was approximately $2.5 billion.
• Projected market value by 2030 is $3.03 billion.
• This represents a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030.

To be fair, the upfront payment SciSparc Ltd. hopes to replicate was $3 million received by Xylo for Greater China commercialization in 2019. Finance: draft 13-week cash view by Friday.